AmerisourceBergen Corporation.
http://www.amerisourcebergen.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AmerisourceBergen Corporation.
Underwater: Medicare Negotiated Prices For Part B Cancer Drugs Could Change Prescribing
Anticipation that reimbursement for significantly discounted Keytruda and Opdivo won’t keep them afloat will influence treatment decisions by oncology providers, officials predict.
Henlius Announces Positive Phase I/II Results For Ophthalmic Bevacizumab Biosimilar
Henlius has successfully established the safety and preliminary efficacy of its ophthalmology-indicated bevacizumab biosimilar HLX04-O in Phase I/II trials.
The Quality Lowdown: As Washington Churns On Drug Shortages, Supply Chain Challenges Grow
While FDA commissioner meets with firms on shortages, senators challenge alternative source of platinum chemotherapies, FDA hinges imports from Sun plant on successful media fill runs, Safe Chain warned on Biktarvy suppliers, and the FDA asks Ipca more questions while setting “Mr. Ye” straight.
How To Develop A Patient-First Strategy For CGT Commercialization
Many new drug commercialization decisions need to happen early in the clinical development of a therapy, and cell and gene treatments are no different. As Amerisource Bergen’s Lung-I Cheng tells In Vivo, creating a patient-first blueprint is the best place to start.
Company Information
- Industry
- Distributors
- Services
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice